CVRx (NASDAQ:CVRX – Get Free Report) and Vycor Medical (OTCMKTS:VYCO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.
Analyst Recommendations
This is a breakdown of current ratings and target prices for CVRx and Vycor Medical, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
CVRx | 0 | 2 | 4 | 0 | 2.67 |
Vycor Medical | 0 | 0 | 0 | 0 | N/A |
CVRx currently has a consensus target price of $13.60, indicating a potential upside of 70.64%. Given CVRx’s higher possible upside, equities research analysts plainly believe CVRx is more favorable than Vycor Medical.
Institutional & Insider Ownership
Profitability
This table compares CVRx and Vycor Medical’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
CVRx | -122.52% | -72.51% | -49.78% |
Vycor Medical | -7.49% | N/A | -10.32% |
Risk and Volatility
CVRx has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, Vycor Medical has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.
Valuation & Earnings
This table compares CVRx and Vycor Medical’s revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
CVRx | $44.39 million | 3.88 | -$41.20 million | ($2.47) | -3.23 |
Vycor Medical | $1.46 million | 2.01 | -$70,000.00 | N/A | N/A |
Vycor Medical has lower revenue, but higher earnings than CVRx.
Summary
CVRx beats Vycor Medical on 7 of the 11 factors compared between the two stocks.
About CVRx
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
About Vycor Medical
Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. It operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System, a retraction and access system for brain and spine surgeries. The NovaVision segment offers non-invasive computer-based rehabilitation targeted at people who have impaired vision as a result of stroke or other brain injury. It has a license agreement which grants for the license to provide NovaVision's products and therapies to patients and professionals in Germany, Austria and Switzerland. It primarily serves hospitals and medical professionals. Vycor Medical, Inc. was founded in 2005 and is headquartered in Boca Raton, Florida. Vycor Medical, Inc. is a subsidiary of Fountainhead Capital Management Limited.
Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.